Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
J Transl Med. 2023 Sep 23;21(1):662. doi: 10.1186/s12967-023-04537-1.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the leading cause of death in diabetic patients, the use of EMPA could be, simultaneously, cardioprotective and antidiabetic, reducing the risk of death from cardiovascular causes and decreasing the risk of hospitalization for heart failure in T2DM patients. Interestingly, recent studies have shown that EMPA has positive benefits for people with and without diabetes. This finding broadens the scope of EMPA function beyond glucose regulation alone to include a more intricate metabolic process that is, in part, still unknown. Similarly, this significantly increases the number of people with heart diseases who may be eligible for EMPA treatment.
This study aimed to clarify the metabolic effect of EMPA on the human myocardial cell model by using orthogonal metabolomics, lipidomics, and proteomics approaches. The untargeted and multivariate analysis mimicked the fasting blood sugar level of T2DM patients (hyperglycemia: HG) and in the average blood sugar range (normal glucose: NG), with and without the addition of EMPA.
Results highlighted that EMPA was able to modulate and partially restore the levels of multiple metabolites associated with cellular stress, which were dysregulated in the HG conditions, such as nicotinamide mononucleotide, glucose-6-phosphate, lactic acid, FA 22:6 as well as nucleotide sugars and purine/pyrimidines. Additionally, EMPA regulated the levels of several lipid sub-classes, in particular dihydroceramide and triacylglycerols, which tend to accumulate in HG conditions resulting in lipotoxicity. Finally, EMPA counteracted the dysregulation of endoplasmic reticulum-derived proteins involved in cellular stress management.
These results could suggest an effect of EMPA on different metabolic routes, tending to rescue cardiomyocyte metabolic status towards a healthy phenotype.
钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂是 2 型糖尿病(T2DM)的金标准治疗方法。其中,恩格列净(EMPA)已显示出对心力衰竭有益的作用。由于心血管疾病(主要是糖尿病性心肌病)是糖尿病患者死亡的主要原因,因此 EMPA 的使用既可以起到心脏保护作用,又可以起到抗糖尿病作用,降低因心血管原因导致的死亡风险,并降低 T2DM 患者因心力衰竭住院的风险。有趣的是,最近的研究表明,EMPA 对有糖尿病和无糖尿病的患者都有积极的益处。这一发现将 EMPA 的功能从单纯的血糖调节扩展到更复杂的代谢过程,而部分代谢过程仍不为人知。同样,这大大增加了可能有资格接受 EMPA 治疗的心脏病患者数量。
本研究旨在通过正交代谢组学、脂质组学和蛋白质组学方法,阐明 EMPA 对人类心肌细胞模型的代谢作用。非靶向和多变量分析模拟了 T2DM 患者的空腹血糖水平(高血糖:HG)和平均血糖范围内(正常血糖:NG),并在有无 EMPA 的情况下进行了分析。
结果突出表明,EMPA 能够调节和部分恢复与细胞应激相关的多种代谢物的水平,这些代谢物在 HG 条件下失调,如烟酰胺单核苷酸、葡萄糖-6-磷酸、乳酸、FA 22:6 以及核苷酸糖和嘌呤/嘧啶。此外,EMPA 调节了几种脂质亚类的水平,特别是二氢神经酰胺和三酰基甘油,它们在 HG 条件下倾向于积累,导致脂毒性。最后,EMPA 逆转了内质网来源的参与细胞应激管理的蛋白质的失调。
这些结果可能表明 EMPA 对不同的代谢途径有影响,倾向于使心肌细胞的代谢状态向健康表型恢复。